[Federal Register Volume 80, Number 235 (Tuesday, December 8, 2015)]
[Notices]
[Pages 76279-76280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30861]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Department of Defense is publishing this notice to
announce a Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (hereafter referred to as the Panel).
DATES: Thursday, January 7, 2016, from 9:00 a.m. to 1:00 p.m.
ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW.,
Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, DFO, Uniform
Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite
5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. Fax:
(703) 681-1940. Email Address: [email protected].
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act of 1972 (Title 5,
United States Code (U.S.C.), Appendix, as amended) and the Government
in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended).
Purpose of Meeting: The Panel will review and comment on
recommendations made to the Director of Defense Health Agency, by the
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.
Meeting Agenda
1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each
agenda item)
a. Attention Deficit Hyperactivity Disorder (ADHD)--Stimulants
b. Antirheumatic Drugs--Methotrexate Injectable
c. Gastrointestinal -2 Agents--Miscellaneous
d. Acne--Isotretinoins
5. Designated Newly Approved Drugs in Already-Reviewed Classes
6. Designated Newly FDA Approved Drugs
7. Pertinent Utilization Management Issues
8. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and
the availability of space, this meeting is open to the public. Seating
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
Administrative Work Meeting: Prior to the public meeting, the Panel
will conduct an Administrative Work Meeting from 7:45 a.m. to 9:00 a.m.
to discuss administrative matters of the
[[Page 76280]]
Panel. The Administrative Work Meeting will be held at the Naval
Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004.
Pursuant to 41 CFR 102-3.160, the Administrative Work Meeting will be
closed to the public.
Written Statements: Pursuant to 41 CFR 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel at any time or in response to the stated agenda
of a planned meeting. Written statements should be submitted to the
Panel's Designated Federal Officer (DFO). The DFO's contact information
can be obtained from the General Services Administration's Federal
Advisory Committee Act Database at http://facadatabase.gov/. Written
statements that do not pertain to the scheduled meeting of the Panel
may be submitted at any time. However, if individual comments pertain
to a specific topic being discussed at a planned meeting, then these
statements must be submitted no later than 5 business days prior to the
meeting in question. The DFO will review all submitted written
statements and provide copies to all the committee members.
Public Comments: In addition to written statements, the Panel will
set aside 1 hour for individuals or interested groups to address the
Panel. To ensure consideration of their comments, individuals and
interested groups should submit written statements as outlined in this
notice; but if they still want to address the Panel, then they will be
afforded the opportunity to register to address the Panel. The Panel's
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for
registration on a first-come, first-serve basis. Those wishing to
address the Panel will be given no more than 5 minutes to present their
comments, and at the end of the 1 hour time period, no further public
comments will be accepted. Anyone who signs-up to address the Panel,
but is unable to do so due to the time limitation, may submit their
comments in writing; however, they must understand that their written
comments may not be reviewed prior to the Panel's deliberation.
To ensure timeliness of comments for the official record, the Panel
encourages that individuals and interested groups consider submitting
written statements instead of addressing the Panel.
Dated: December 3, 2015.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2015-30861 Filed 12-7-15; 8:45 am]
BILLING CODE 5001-06-P